pdufa.bio
Home › PDUFA Calendar › PFE

PFE PDUFA Date: TUKYSA, trastuzumab, and pertuzumab

Page updated ·next FDA decision on the calendar ·Data as of Nov 14, 2026 7:42 PM ET
✓ Approved · the FDA decided this application on October 7, 2026. Decision page with the source and measured reaction.
FDA decision Approved October 7, 2026 · Pfizer Inc. · HER2+ Metastatic Breast Cancer
More Cancer & Oncology FDA decisions →All December 2026 PDUFA dates →

The story

TUKYSA, trastuzumab, and pertuzumab was approved by the FDA on October 7, 2026 to treat HER2+ Metastatic Breast Cancer.
Plain-English summary compiled by pdufa.bio from public FDA, SEC and company sources. Informational only - not investment advice.

PFE run-up into the PDUFA (last ~120 days)

$28.55$25.33
Price path to 2026-06-19. Green = local high, red = low/sell-off. Historical price action, not a forecast.

Key facts

FDA decisionApproved October 7, 2026
Drug / candidateTUKYSA, trastuzumab, and pertuzumab
IndicationHER2+ Metastatic Breast Cancer
CompanyPfizer Inc.
Market-cap tierLarge
Cohort decision-day move (history)1.0% median (n=898)
ClinicalTrials.govNot listed

New to FDA decisions? Read what a PDUFA date is and how often the FDA approves drugs.

See the full 2026 PDUFA calendar →

FAQ

What did the FDA decide on PFE's TUKYSA, trastuzumab, and pertuzumab?
The FDA decided PFE's (Pfizer Inc.) application for TUKYSA, trastuzumab, and pertuzumab on October 7, 2026: Approved. pdufa.bio does not hold a sponsor-disclosed goal date for this application. Verify against the linked primary source.
What is PFE's drug TUKYSA, trastuzumab, and pertuzumab?
TUKYSA, trastuzumab, and pertuzumab is Pfizer Inc.'s drug, approved by the FDA on October 7, 2026 for HER2+ Metastatic Breast Cancer.
What typically happens to a large-cap stock into a PDUFA date?
Historically, large-cap names had a median decision-day move of 1.0% in either direction (898 large-cap decisions in our 1,886-decision run-up study, 2020-26). This is historical context by market-cap tier, not a prediction for this drug.
Decision-day move · large-cap cohortn=790 · median +0.0% · 50% up
under -30%: 2 of 790 (0%)<-30-30 to -15%: 2 of 790 (0%)-15 to -7%: 6 of 790 (1%)-7 to -3%: 29 of 790 (4%)-3 to +3%: 707 of 790 (89%)±3+3 to +7%: 35 of 790 (4%)+7 to +15%: 5 of 790 (1%)+15 to +30%: 2 of 790 (0%)over +30%: 2 of 790 (0%)>+30
Distribution of next-day % moves after the FDA decision for large-cap PDUFAs (2020–26). Red = down, green = up, blue = flat (±3%). Historical dispersion, not a forecast.